Drugs / ABT-SLV187
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01479127 | Oct 2011 → Jul 2012 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02082249 | Mar 2014 → Oct 2019 | Parkinson disease | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-SLV187 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01479127 ↗ |
| Route | Other | “administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube” NCT01479127 ↗ |